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Background: The Japan-Multinational Trial Organization (JMTO)
lung cancer (LC) 0003 was a prospective randomized phase III trial
investigating advanced non-small cell lung cancer comparing pac-
litaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine
(G) followed by docetaxel (D). This trial was conducted with
Southwest Oncology Group (SWOG) 0003 using a common arm of
PC. An analysis of SWOG 0003 samples showed that low osteopon-
tin (OPN) plasma levels were highly prognostic for a better out-
come. We performed an independent investigation to validate these
results using samples from Japanese patients enrolled in the JMTO
LC 0004, a correlative study associated with JMTO LC 0003.
Methods: A total of 20 ml of blood was collected before treatment
from patients enrolled in JMTO LC 0003. Serum concentrations of
OPN and basic fibroblast growth factor (bFGF) were measured by
enzyme-linked immunosorbent assay. Effects of OPN and bFGF
levels on tumor response, progression-free survival (PFS), and
overall survival (OS) were examined.
Results: Seventy-one samples were obtained, including 32 speci-
mens from the PC arm and 39 from the VGD arm. There were no
significant relationships between either OPN or bFGF levels with
patient characteristics. In an analysis of clinical outcome, low OPN
levels correlated with better OS and progression-free survival (haz-
ard ratio [HR] 0.57; 95% confidence interval [CI], 0.33–0.97; p
0.037, HR 0.42; 95% CI, 0.25–0.70; p 0.001, respectively) and
high bFGF levels correlated with better OS (HR  0.53; 95% CI,
0.31–0.90; p  0.018).
Conclusion: Consistent with the findings from SWOG 0003, low
OPN serum levels were significantly associated with a favorable
prognosis in the JMTO LC 0004. Additionally, high bFGF levels
were associated with improved survival.
Key Words: Non-small cell lung cancer, Osteopontin, bFGF,
Correlative study.
(J Thorac Oncol. 2009;4: 1104–1110)
Lung cancer (LC) is the most common cause of death dueto cancer in Japan and in the United States.1,2 Non-small
cell LC (NSCLC) accounts for about 80 to 85% of LC
histology in both countries,3 and most patients with NSCLC
have either locally advanced or metastatic disease at the time
of diagnosis. Because currently available treatments still
provide only a modest increase in overall survival (OS) for
patients with advanced NSCLC, identification of prognostic
and/or predictive biomarkers would be important. Global
clinical trials have been conducted, and international efforts
to develop predictive/prognostic biomarkers should also be
made to improve clinical outcome in patients with advanced
NSCLC.
A prospective randomized phase III trial conducted for
advanced NSCLC compared paclitaxel (P) plus carboplatin
(C) versus vinorelbine (V), gemcitabine (G) followed by
docetaxel (D) in the Japan-Multinational Trial Organization
(JMTO).4 A total of 401 patients were enrolled and 393 were
eligible. This trial was conducted with Southwest Oncology
Group (SWOG) 0003 using a “common arm” of PC. The
common arm concept was designed to prospectively evaluate
Japanese and U.S. populations using equivalent patient eligi-
bility criteria, staging, and treatment.5 SWOG 0003 was a
phase III trial investigating PC with or without tirapazamine
in advanced NSCLC. A correlative study conducted on spec-
imens from SWOG 0003 showed that low osteopontin (OPN)
plasma levels were associated with a better survival regard-
less of the treatment arm. They concluded that OPN plasma
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levels can be considered as a prognostic biomarker in che-
motherapy-treated patients with advanced NSCLC.6
OPN is a phosphorylated acid glycoprotein with a
diverse range of biologic activities.7 Secreted OPN interacts
with members of the integrin family and variants of CD44,
stimulating a variety of downstream processes associated
with tumor progression or cellular transformation.8–10 OPN
induces an expression of urokinase-type plasminogen activa-
tor and increases the cell migration and adhesion, contribut-
ing to cellular transformation and metastasis.11–14 Through
this process, OPN is associated with angiogenesis, leading to
a more aggressive tumor phenotype. Moreover, OPN was
shown to be associated with clinical prognosis in various
tumor types including LC.15,16
On the other hand, basic fibroblast growth factor
(bFGF) is a proangiogenic growth factor, which is encoded
by a single copy gene and has several isoforms ranging in size
from 18 to 24 kd, including a heparin-binding domain.17 It
acts as a mitogenic and chemotactic stimulant for endothelial
cells and can synergize with vascular endothelial growth
factor to promote tumor angiogenesis. Overexpression of
bFGF in LC is reported to be closely involved in cancer
proliferation and is associated with prognosis.18,19
In JMTO LC 0004 (the correlative study of JMTO LC
0003; Ref. 4), we elected to study the prognostic value of
OPN and bFGF in our patient population. We hypothesized
that serum levels of OPN and bFGF would correlate with
patient outcomes. Here, we report results demonstrating that
OPN concentrations were significantly associated with prog-
nosis in patients with NSCLC, consistent with the results
from SWOG 0003.
PATIENTS AND METHODS
Study Population and Sample Collection
Blood specimens were obtained from consenting pa-
tients with histologically or cytologically confirmed stage
IIIB (positive pleural effusion) or stage IV disease (no brain
metastases) enrolled in JMTO LC 0003. Approximately 20
ml of peripheral blood was collected before treatment from
patients electing to enroll in JMTO LC 0004. Serum was
isolated and stored in aliquots at 80°C.
Measurement of Serum OPN and bFGF
Concentrations
Serum was separated from peripheral blood by micro-
centrifuge at 3000 rpm at room temperature. Serum concen-
trations of OPN and bFGF were measured using the Quan-
tikine Human OPN immunoassay kit (DOST00; R&D
systems, Minneapolis, MN) according to the manufacturer’s
instructions. Briefly, 1:25 diluted samples were incubated in
OPN or bFGF antibody-precoated plates for 2 hours at room
temperature. After washing, 200 l of labeled OPN or bFGF
conjugate solution was added to each well and incubated for
2 hours at room temperature. After washing, a substrate
solution containing tetramethylbenzidine was used as a col-
oring agent. Measurements were taken on a plate reader
(Model 550 Microplate Reader; Bio-Rad Laboratories, Her-
cules, CA) at 450 nm with wavelength correction at 550 nm.
Statistical Analysis
The relationships between OPN/bFGF levels, and pa-
tients characteristics were examined using the 2 test, includ-
ing treatment arm, age, smoking status, histology, clinical
stage, performance status, weight loss, and lactate dehydro-
genase. Effects of OPN and bFGF levels on tumor response
were examined using the logistic regression analysis. Pro-
gression-free survival (PFS) and OS curves were calculated
using the Kaplan-Meier method and analyzed by the log-rank
test. Statistical analyses were done using SAS version 9.1
(SAS Institute, Cary, NC).
RESULTS
Serum OPN and bFGF Levels of Patients with
NSCLC in LC 0004
Seventy-one samples were obtained, including 32 spec-
imens from the PC arm and 39 from the VGD arm. Serum
OPN levels of 67 patients ranged from 17.5 to 300.4 ng/ml,
with a median value of 69.0 ng/ml. Serum bFGF level in 71
patients ranged from 0.3 to 133.1 ng/ml, with a median value
of 14.9 ng/ml. No correlation was observed between serum
levels of OPN and bFGF (Spearman’s r  0.264).
Patient Characteristics by Median Levels
We analyzed the association between patient character-
istics and tumor marker status stratified at the median (Tables
1, 2). Smokers trended toward having higher OPN levels (p
0.083); however, no other relationships were observed.
Response
Patients were dichotomized at the median serum con-
centrations of OPN and bFGF and were examined for rela-
tionships with tumor response. The response rate was 18% (6
of 34) in patients with high OPN levels and 33% (11 of 33)
in those with low OPN levels. In patients with high bFGF
levels, response rates were 25% (9 of 36) compared with 29%
(10 of 35) in those with low bFGF levels. Differences in
response rates between high and low biomarker concentra-
tions were not significant (OPN: OR  0.43, 95% confidence
interval [CI]: 0.14–1.34, p  0.145; bFGF: OR  0.83, 95%
CI: 0.29–2.39, p  0.734).
Serum Levels of OPN and bFGF are Prognostic
for Patient Survival
The relationship between OPN and bFGF and patient
survival was investigated. Kaplan-Meier plots for OS and
PFS are shown in Figures 1 and 2, respectively. Patients were
dichotomized according to median serum levels of OPN and
bFGF. Those with OPN levels below the median showed a
significantly favorable OS and PFS (hazard ratio [HR] 
0.57; 95% CI: 0.33–0.97; p  0.037; HR  0.42; 95% CI:
0.25–0.70; p  0.001, respectively; Figures 1A, B). When
examined as a continuous variable, OPN levels also had a
significant association with both OS and PFS (HR  1.006;
95% CI: 1.001–1.011; p  0.021; HR  1.008; 95% CI:
1.003–1.013; p  0.002, respectively).
Patients with bFGF levels above the median showed
significantly improved survival compared with those with
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levels below the median (HR  0.53, 95% CI: 0.31–0.90,
p  0.018; Figure 2A). However, this association did not
achieve significance for PFS (p  0.192; Figure 2B).
The multiparametric analysis using both markers is
shown in Figure 3. The cases were stratified according to
OPN and bFGF levels into four groups: group 1, OPN less
than median level/bFGF more than median level; group 2,
OPN less than median level/bFGF less than median level;
group 3, OPN more than median level/bFGF more than
median level; and group 4, OPN more than median level/
bFGF less than median level. Assuming group 4 as a refer-
ence, the patients of group 1 had significantly better OS and
PFS (OS: HR  0.21, 95% CI: 0.09–0.50, p  0.001; PFS:
HR  0.23, 95% CI: 0.10–0.53, p  0.001).
DISCUSSION
We demonstrated that low OPN serum levels were
significantly associated with a favorable prognosis in the
Japanese patients, which is consistent with findings from
SWOG 0003 in the U.S. population.6 In addition, high bFGF
levels were also associated with improved patient survival.
JMTO LC 0004, a correlative study of JMTO LC 0003,
was originally designed to assess -tubulin mutations and
methylation of DNA repair gene in the patient serum as
biomarkers. However, the former was determined to be in-
significant,20,21 and in the latter, we failed to detect sufficient
tumor DNA in the serum for analysis. We had planned to
keep patient specimens for future analysis as a secondary end
point. The JMTO LC 0003 was conducted with SWOG 0003
using a common arm of PC. As for ethnicity, there was a
marked difference between the two trials. Exclusively, our
study included Japanese patients, whereas in SWOG, most
patients were African American.
For collaboration with SWOG 0003, we performed two
additional studies using the stock samples approved by the
JMTO Institutional Review Board. We previously collabo-
rated on pharmacogenomic studies of patient samples ana-
lyzed from both trials. Gandara et al. found significant dif-
ferences in survival and toxicity between the two populations.
The Japanese patients with advanced NSCLC lived longer
and had more severe side effects compared with the U.S.
population. Median survival time was 14 months in the
TABLE 1. Patient Characteristics by Osteopontin
Osteopontin
<69 ng/ml
(n  33), n (%)
Osteopontin
>69 ng/ml
(n  34), n (%) p
Treatment
PC 16 (48) 17 (50) 1.000
VGD 17 (52) 17 (50)
Age (yr)
Median 66 63 0.198
Range 40–79 51–79
Sex
Male 21 (64) 25 (74) 0.437
Female 12 (36) 9 (26)
Smoking
Never smoker 15 (45) 7 (21) 0.083
Former smoker 9 (27) 11 (32)
Current smoker 9 (27) 16 (47)
Histology
Squamous cell 8 (24) 7 (21) 0.321
Adenocarcinoma 25 (76) 24 (70)
Other 0 (0) 3 (9)
Stage
IIIB 7 (21) 11 (32) 1.000
IV 26 (79) 23 (68)
Performance status
0 7 (21) 11 (32) 0.410
1 26 (79) 23 (68)
Weight loss
5% 26 (79) 29 (85) 0.539
5% 7 (21) 5 (15)
Lactate dehydrogenase
Normal 27 (82) 28 (82) 1.000
Abnormal 6 (18) 6 (18)
PC, paclitaxel (P) plus carboplatin (C); VGD, vinorelbine (V), gemcitabine (G)
followed by docetaxel (D).
TABLE 2. Patient Characteristics by bFGF
bFGF
<14.9 ng/ml
(n  35), n (%)
bFGF
>14.9 ng/ml
(n  36), n (%) p
Treatment
PC 18 (51) 14 (39) 0.0344
VGD 17 (49) 22 (61)
Age (yr)
Median 66 65 0.607
Range 51–76 48–79
Sex
Male 28 (80) 25 (69) 0.415
Female 7 (20) 11 (31)
Smoking
Never smoker 10 (29) 10 (28) 0.793
Former smoker 11 (31) 9 (25)
Current smoker 14 (40) 17 (47)
Histology
Squamous cell 10 (29) 5 (14) 0.294
Adenocarcinoma 23 (66) 28 (78)
Other 2 (6) 3 (8)
Stage
IIIB 9 (26) 8 (28) 0.786
IV 26 (74) 28 (72)
Performance status
0 8 (23) 11 (31) 0.594
1 27 (77) 25 (69)
Weight loss
5% 30 (86) 29 (81) 0.753
5% 5 (14) 7 (19)
Lactate dehydrogenase
Normal 24 (69) 31 (86) 0.094
Abnormal 11 (31) 6 (14)
bFGF, basic fibroblast growth factor; PC, paclitaxel (P) plus carboplatin (C); VGD,
vinorelbine (V), gemcitabine (G) followed by docetaxel (D).
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Japanese patients, whereas it was 9 months in the U.S.
patients, and neutropenia for toxicity was observed in 70% of
Japanese patients compared with 38% in the U.S. patients.
Significant differences in allelic distribution for genes in-
volved in paclitaxel disposition and DNA repair were ob-
served between Japanese and U.S. patients.5
Additional analysis of SWOG 0003 samples conducted
previously showed that OPN was a prognostic marker, indepen-
dent of treatment arm.6 We then sought to determine whether
these results would be recapitulated in Japanese patients from
the JMTO LC 0004. In this study, we found OPN to be a useful
and prognostic marker in patients with NSCLC independent of
ethnicity, despite the clinical and pharmacogenomic differences
observed between the populations mentioned earlier.
Consistent with the SWOG study, we found that the
patients with low OPN had a significantly better OS and PFS
(HR  0.57; 95% CI: 0.33–0.97; p  0.037; HR  0.42; 95%
CI: 0.25–0.70; p  0.001, respectively) when dichotomized at
the median and as a continuous variable. OPN has been reported
to be involved in tumor invasion and metastasis. High OPN
serum levels have been correlated to increased invasion in solid
tumors,22 which is suggested to predict worse prognosis.
In the treatment response rate, OPN levels were also
a significant predictive marker in the SWOG study, but we
FIGURE 1. Overall survival and
progression-free survival by serum
OPN level. A, Overall survival
(Kaplan-Meier) plot showing pa-
tients divided into higher or lower
than the median serum concentra-
tion of OPN (69 ng/ml). Patients with
lower OPN levels (solid line) showed
significantly better overall survival
compared with those with higher lev-
els (dotted line). B, Patients with lower
OPN levels (solid line) had significantly
better progression-free survival com-
pared with those with higher levels
(dotted line; p  0.001). OPN,
osteopontin.
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could not confirm these results. It was reported that PFS
was significantly associated with response rate in LC
patients,23 and the significant relationship between OPN
level and PFS in this study may indicate that our lack
of statistical significance is perhaps because of the limi-
ted sample size. However, we cannot rule out the diffe-
rent types of drugs used in the experimental arms in the
two trials.
In this study, we also found that serum bFGF levels
were a prognostic factor in patients with NSCLC. The low
OPN/high bFGF group had the most favorable survival in
a multiparametric model, suggesting that adding bFGF
analysis enhances the prognosis value of OPN. Previously,
we reported that bFGF showed no correlation with survival
in 60 patients with stage I–IV NSCLC. The difference in
the results is partly because of the clinical stage of the
patients examined. To date, there have been four studies on
the prognostic value of circulating bFGF; three studies
reported a negative prognostic impact, whereas one indi-
cated bFGF as a favorable prognostic factor.24 Yiangou et
al.25 reported that patients with high expression of bFGF
had better outcomes than patients with low expression in
breast cancer. Although bFGF is a potent mitogenic factor,
they suggested that bFGF contributes to the maintenance
of differentiation of the duct rather than cell proliferation
in breast cancer. Also, elevated levels of serum bFGF
FIGURE 2. Overall survival and
progression-free survival by bFGF
serum level. A, Overall survival
(Kaplan-Meier) plot showing pa-
tients divided into higher or lower
than the median serum concentra-
tion of bFGF (14.9 ng/ml). Patients
with higher bFGF levels (dotted
line) had significantly better overall
survival compared with those with
lower levels (solid line; p  0.03). B,
There was no significant association
between bFGF level and progres-
sion-free survival. bFGF, basic fibro-
blast growth factor.
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might contribute to abundant vascular bed formation in LC
and more anticancer drugs might reach cancer cells.26
Given these suggestions, improved clinical outcome might
be shown in the patients with high bFGF. However, it is
still controversial as to whether bFGF is predictive of
outcome in patients treated with chemotherapy. These
results need to be confirmed by further examination.
Limitations of the current study include a small sample
size. JMTO LC 0004 is a correlative study and had a protocol
different from LC 0003. Not all the investigators participated
in it, which might result in the low percentage of patient
samples analyzed. Another problem in this study is a long
period for accrual for the clinical trial; we needed 4 years to
complete the trial and the end point had to be changed
through scientific advancement. This study highlights the
importance of collecting and retaining patient samples for
future research.
In conclusion, consistent with findings from SWOG
0003, low OPN serum levels were significantly associated
with a favorable prognosis in the JMTO LC 0004. OPN
FIGURE 3. The multiparametric
model showed that the patients of
group 1 had significantly better OS
and PFS compared with group 4
patients (OS: HR  0.21, 95%
CI: 0.09–0.50, p  0.001; PFS:
HR  0.23, 95% CI: 0.10–0.53,
p  0.001). Patients were subdi-
vided into four groups based on
OPN and bFGF serum levels: group
1, OPN less than median level/
bFGF more than median level;
group 2, OPN less than median
level/bFGF less than median level;
group 3, OPN more than median
level/bFGF more than median level;
and group 4, OPN more than me-
dian level/bFGF less than median
level. OPN, osteopontin; bFGF, ba-
sic fibroblast growth factor; OS,
overall survival; PFS, progression-
free survival.
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will be a useful biomarker to predict prognosis in patients
with NSCLC to be tested in future multinational clinical
trials.
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